drugset / Trial / NCT00028821

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

NCT00028821 ↗

Phase 1 Completed 60 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of 2-methoxyestradiol in treating patients who have advanced solid tumors. 2-methoxyestradiol may stop or slow the growth of solid tumors by stopping blood flow to the tumor

Timeline

Start
2002-01
Primary completion
2006-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-methoxyestradiol Small molecule — Oral